Detail of "131123-76-7"

Reference

Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells

All Rights Reserved. Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells. Pfeffer, Bruce; Flick, Rosemarie; Bartels, Stephen (Bausch & Lomb Incorporated, USA). PCT Int. Appl. WO 2007002781 A2 4 Jan 2007, 33pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2006-US25240 28 Jun 2006. PRIORITY: US 2005-694726P 28 Jun 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) This invention relates to prepns. for controlling intraocular pressure in the eye comprise as an active compd., arylazine substituted with a carbonylic moiety, which compd. is capable of effecting a "pharmacol. trabeculocanalotomy" in an eye by means of reducing juxtacanalicular meshwork to promote outflow of aq. The org. active compd. increases Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aq. outflow as a treatment for glaucoma, e.g. 131123-76-7 and 122-75-8 are just another two chemicals used in this study., primary open angle glaucoma. Thus, kynureic acid was tested for MT-MMPs activity. .